Global Overactive Bladder (OAB) Bionic Drug Market Growth (Status and Outlook) 2025-2031

March 2025 | 98 pages | ID: GD96D713AFCCEN
LP Information

Abstracts

The global Overactive Bladder (OAB) Bionic Drug market size is predicted to grow from US$ 4921 million in 2025 to US$ 5385 million in 2031; it is expected to grow at a CAGR of 1.5% from 2025 to 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Overactive Bladder (OAB) Bionic Drug Industry Forecast” looks at past sales and reviews total world Overactive Bladder (OAB) Bionic Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Overactive Bladder (OAB) Bionic Drug sales for 2025 through 2031. With Overactive Bladder (OAB) Bionic Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Overactive Bladder (OAB) Bionic Drug industry.

This Insight Report provides a comprehensive analysis of the global Overactive Bladder (OAB) Bionic Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Overactive Bladder (OAB) Bionic Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Overactive Bladder (OAB) Bionic Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Overactive Bladder (OAB) Bionic Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Overactive Bladder (OAB) Bionic Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Overactive Bladder (OAB) Bionic Drug market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Anticholinergics
• Mirabegron
• Botox
• Others

Segmentation by Application:

• Idiopathic Overactive Bladder
• Neurogenic Overactive Bladder

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• AbbVie
• Astellas Pharma
• Pfizer
• Teva
• Johnson & Johnson
• Kyorin Pharmaceutical
• Tianjin Pacific Pharmaceutical Co., Ltd.
• Nanjing Meirui Pharma Co., Ltd.
• DIKANG
• Nanjing Zenkom Pharmaceutical Co., Ltd.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Overactive Bladder (OAB) Bionic Drug Market Size (2020-2031)
  2.1.2 Overactive Bladder (OAB) Bionic Drug Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Overactive Bladder (OAB) Bionic Drug by Country/Region (2020, 2024 & 2031)
2.2 Overactive Bladder (OAB) Bionic Drug Segment by Type
  2.2.1 Anticholinergics
  2.2.2 Mirabegron
  2.2.3 Botox
  2.2.4 Others
2.3 Overactive Bladder (OAB) Bionic Drug Market Size by Type
  2.3.1 Overactive Bladder (OAB) Bionic Drug Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Type (2020-2025)
2.4 Overactive Bladder (OAB) Bionic Drug Segment by Application
  2.4.1 Idiopathic Overactive Bladder
  2.4.2 Neurogenic Overactive Bladder
2.5 Overactive Bladder (OAB) Bionic Drug Market Size by Application
  2.5.1 Overactive Bladder (OAB) Bionic Drug Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Application (2020-2025)

3 OVERACTIVE BLADDER (OAB) BIONIC DRUG MARKET SIZE BY PLAYER

3.1 Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Player
  3.1.1 Global Overactive Bladder (OAB) Bionic Drug Revenue by Player (2020-2025)
  3.1.2 Global Overactive Bladder (OAB) Bionic Drug Revenue Market Share by Player (2020-2025)
3.2 Global Overactive Bladder (OAB) Bionic Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 OVERACTIVE BLADDER (OAB) BIONIC DRUG BY REGION

4.1 Overactive Bladder (OAB) Bionic Drug Market Size by Region (2020-2025)
4.2 Global Overactive Bladder (OAB) Bionic Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Overactive Bladder (OAB) Bionic Drug Market Size Growth (2020-2025)
4.4 APAC Overactive Bladder (OAB) Bionic Drug Market Size Growth (2020-2025)
4.5 Europe Overactive Bladder (OAB) Bionic Drug Market Size Growth (2020-2025)
4.6 Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Overactive Bladder (OAB) Bionic Drug Market Size by Country (2020-2025)
5.2 Americas Overactive Bladder (OAB) Bionic Drug Market Size by Type (2020-2025)
5.3 Americas Overactive Bladder (OAB) Bionic Drug Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Overactive Bladder (OAB) Bionic Drug Market Size by Region (2020-2025)
6.2 APAC Overactive Bladder (OAB) Bionic Drug Market Size by Type (2020-2025)
6.3 APAC Overactive Bladder (OAB) Bionic Drug Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Overactive Bladder (OAB) Bionic Drug Market Size by Country (2020-2025)
7.2 Europe Overactive Bladder (OAB) Bionic Drug Market Size by Type (2020-2025)
7.3 Europe Overactive Bladder (OAB) Bionic Drug Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Overactive Bladder (OAB) Bionic Drug by Region (2020-2025)
8.2 Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size by Type (2020-2025)
8.3 Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL OVERACTIVE BLADDER (OAB) BIONIC DRUG MARKET FORECAST

10.1 Global Overactive Bladder (OAB) Bionic Drug Forecast by Region (2026-2031)
  10.1.1 Global Overactive Bladder (OAB) Bionic Drug Forecast by Region (2026-2031)
  10.1.2 Americas Overactive Bladder (OAB) Bionic Drug Forecast
  10.1.3 APAC Overactive Bladder (OAB) Bionic Drug Forecast
  10.1.4 Europe Overactive Bladder (OAB) Bionic Drug Forecast
  10.1.5 Middle East & Africa Overactive Bladder (OAB) Bionic Drug Forecast
10.2 Americas Overactive Bladder (OAB) Bionic Drug Forecast by Country (2026-2031)
  10.2.1 United States Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.2.2 Canada Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.2.3 Mexico Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.2.4 Brazil Market Overactive Bladder (OAB) Bionic Drug Forecast
10.3 APAC Overactive Bladder (OAB) Bionic Drug Forecast by Region (2026-2031)
  10.3.1 China Overactive Bladder (OAB) Bionic Drug Market Forecast
  10.3.2 Japan Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.3.3 Korea Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.3.4 Southeast Asia Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.3.5 India Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.3.6 Australia Market Overactive Bladder (OAB) Bionic Drug Forecast
10.4 Europe Overactive Bladder (OAB) Bionic Drug Forecast by Country (2026-2031)
  10.4.1 Germany Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.4.2 France Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.4.3 UK Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.4.4 Italy Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.4.5 Russia Market Overactive Bladder (OAB) Bionic Drug Forecast
10.5 Middle East & Africa Overactive Bladder (OAB) Bionic Drug Forecast by Region (2026-2031)
  10.5.1 Egypt Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.5.2 South Africa Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.5.3 Israel Market Overactive Bladder (OAB) Bionic Drug Forecast
  10.5.4 Turkey Market Overactive Bladder (OAB) Bionic Drug Forecast
10.6 Global Overactive Bladder (OAB) Bionic Drug Forecast by Type (2026-2031)
10.7 Global Overactive Bladder (OAB) Bionic Drug Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Overactive Bladder (OAB) Bionic Drug Forecast

11 KEY PLAYERS ANALYSIS

11.1 AbbVie
  11.1.1 AbbVie Company Information
  11.1.2 AbbVie Overactive Bladder (OAB) Bionic Drug Product Offered
  11.1.3 AbbVie Overactive Bladder (OAB) Bionic Drug Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 AbbVie Main Business Overview
  11.1.5 AbbVie Latest Developments
11.2 Astellas Pharma
  11.2.1 Astellas Pharma Company Information
  11.2.2 Astellas Pharma Overactive Bladder (OAB) Bionic Drug Product Offered
  11.2.3 Astellas Pharma Overactive Bladder (OAB) Bionic Drug Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Astellas Pharma Main Business Overview
  11.2.5 Astellas Pharma Latest Developments
11.3 Pfizer
  11.3.1 Pfizer Company Information
  11.3.2 Pfizer Overactive Bladder (OAB) Bionic Drug Product Offered
  11.3.3 Pfizer Overactive Bladder (OAB) Bionic Drug Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Pfizer Main Business Overview
  11.3.5 Pfizer Latest Developments
11.4 Teva
  11.4.1 Teva Company Information
  11.4.2 Teva Overactive Bladder (OAB) Bionic Drug Product Offered
  11.4.3 Teva Overactive Bladder (OAB) Bionic Drug Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Teva Main Business Overview
  11.4.5 Teva Latest Developments
11.5 Johnson & Johnson
  11.5.1 Johnson & Johnson Company Information
  11.5.2 Johnson & Johnson Overactive Bladder (OAB) Bionic Drug Product Offered
  11.5.3 Johnson & Johnson Overactive Bladder (OAB) Bionic Drug Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 Johnson & Johnson Main Business Overview
  11.5.5 Johnson & Johnson Latest Developments
11.6 Kyorin Pharmaceutical
  11.6.1 Kyorin Pharmaceutical Company Information
  11.6.2 Kyorin Pharmaceutical Overactive Bladder (OAB) Bionic Drug Product Offered
  11.6.3 Kyorin Pharmaceutical Overactive Bladder (OAB) Bionic Drug Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Kyorin Pharmaceutical Main Business Overview
  11.6.5 Kyorin Pharmaceutical Latest Developments
11.7 Tianjin Pacific Pharmaceutical Co., Ltd.
  11.7.1 Tianjin Pacific Pharmaceutical Co., Ltd. Company Information
  11.7.2 Tianjin Pacific Pharmaceutical Co., Ltd. Overactive Bladder (OAB) Bionic Drug Product Offered
  11.7.3 Tianjin Pacific Pharmaceutical Co., Ltd. Overactive Bladder (OAB) Bionic Drug Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Tianjin Pacific Pharmaceutical Co., Ltd. Main Business Overview
  11.7.5 Tianjin Pacific Pharmaceutical Co., Ltd. Latest Developments
11.8 Nanjing Meirui Pharma Co., Ltd.
  11.8.1 Nanjing Meirui Pharma Co., Ltd. Company Information
  11.8.2 Nanjing Meirui Pharma Co., Ltd. Overactive Bladder (OAB) Bionic Drug Product Offered
  11.8.3 Nanjing Meirui Pharma Co., Ltd. Overactive Bladder (OAB) Bionic Drug Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 Nanjing Meirui Pharma Co., Ltd. Main Business Overview
  11.8.5 Nanjing Meirui Pharma Co., Ltd. Latest Developments
11.9 DIKANG
  11.9.1 DIKANG Company Information
  11.9.2 DIKANG Overactive Bladder (OAB) Bionic Drug Product Offered
  11.9.3 DIKANG Overactive Bladder (OAB) Bionic Drug Revenue, Gross Margin and Market Share (2020-2025)
  11.9.4 DIKANG Main Business Overview
  11.9.5 DIKANG Latest Developments
11.10 Nanjing Zenkom Pharmaceutical Co., Ltd.
  11.10.1 Nanjing Zenkom Pharmaceutical Co., Ltd. Company Information
  11.10.2 Nanjing Zenkom Pharmaceutical Co., Ltd. Overactive Bladder (OAB) Bionic Drug Product Offered
  11.10.3 Nanjing Zenkom Pharmaceutical Co., Ltd. Overactive Bladder (OAB) Bionic Drug Revenue, Gross Margin and Market Share (2020-2025)
  11.10.4 Nanjing Zenkom Pharmaceutical Co., Ltd. Main Business Overview
  11.10.5 Nanjing Zenkom Pharmaceutical Co., Ltd. Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION


LIST OFTABLES

Table 1. Overactive Bladder (OAB) Bionic Drug Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Overactive Bladder (OAB) Bionic Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Anticholinergics
Table 4. Major Players of Mirabegron
Table 5. Major Players of Botox
Table 6. Major Players of Others
Table 7. Overactive Bladder (OAB) Bionic Drug Market Size CAGR byType (2020 VS 2024 VS 2031) & ($ millions)
Table 8. Global Overactive Bladder (OAB) Bionic Drug Market Size byType (2020-2025) & ($ millions)
Table 9. Global Overactive Bladder (OAB) Bionic Drug Market Size Market Share byType (2020-2025)
Table 10. Overactive Bladder (OAB) Bionic Drug Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Overactive Bladder (OAB) Bionic Drug Market Size by Application (2020-2025) & ($ millions)
Table 12. Global Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Application (2020-2025)
Table 13. Global Overactive Bladder (OAB) Bionic Drug Revenue by Player (2020-2025) & ($ millions)
Table 14. Global Overactive Bladder (OAB) Bionic Drug Revenue Market Share by Player (2020-2025)
Table 15. Overactive Bladder (OAB) Bionic Drug Key Players Head office and Products Offered
Table 16. Overactive Bladder (OAB) Bionic Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Overactive Bladder (OAB) Bionic Drug Market Size by Region (2020-2025) & ($ millions)
Table 20. Global Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Region (2020-2025)
Table 21. Global Overactive Bladder (OAB) Bionic Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 22. Global Overactive Bladder (OAB) Bionic Drug Revenue Market Share by Country/Region (2020-2025)
Table 23. Americas Overactive Bladder (OAB) Bionic Drug Market Size by Country (2020-2025) & ($ millions)
Table 24. Americas Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Country (2020-2025)
Table 25. Americas Overactive Bladder (OAB) Bionic Drug Market Size byType (2020-2025) & ($ millions)
Table 26. Americas Overactive Bladder (OAB) Bionic Drug Market Size Market Share byType (2020-2025)
Table 27. Americas Overactive Bladder (OAB) Bionic Drug Market Size by Application (2020-2025) & ($ millions)
Table 28. Americas Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Application (2020-2025)
Table 29. APAC Overactive Bladder (OAB) Bionic Drug Market Size by Region (2020-2025) & ($ millions)
Table 30. APAC Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Region (2020-2025)
Table 31. APAC Overactive Bladder (OAB) Bionic Drug Market Size byType (2020-2025) & ($ millions)
Table 32. APAC Overactive Bladder (OAB) Bionic Drug Market Size by Application (2020-2025) & ($ millions)
Table 33. Europe Overactive Bladder (OAB) Bionic Drug Market Size by Country (2020-2025) & ($ millions)
Table 34. Europe Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Country (2020-2025)
Table 35. Europe Overactive Bladder (OAB) Bionic Drug Market Size byType (2020-2025) & ($ millions)
Table 36. Europe Overactive Bladder (OAB) Bionic Drug Market Size by Application (2020-2025) & ($ millions)
Table 37. Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size by Region (2020-2025) & ($ millions)
Table 38. Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size byType (2020-2025) & ($ millions)
Table 39. Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size by Application (2020-2025) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Overactive Bladder (OAB) Bionic Drug
Table 41. Key Market Challenges & Risks of Overactive Bladder (OAB) Bionic Drug
Table 42. Key IndustryTrends of Overactive Bladder (OAB) Bionic Drug
Table 43. Global Overactive Bladder (OAB) Bionic Drug Market SizeForecast by Region (2026-2031) & ($ millions)
Table 44. Global Overactive Bladder (OAB) Bionic Drug Market Size Market ShareForecast by Region (2026-2031)
Table 45. Global Overactive Bladder (OAB) Bionic Drug Market SizeForecast byType (2026-2031) & ($ millions)
Table 46. Global Overactive Bladder (OAB) Bionic Drug Market SizeForecast by Application (2026-2031) & ($ millions)
Table 47. AbbVie Details, CompanyType, Overactive Bladder (OAB) Bionic Drug Area Served and Its Competitors
Table 48. AbbVie Overactive Bladder (OAB) Bionic Drug Product Offered
Table 49. AbbVie Overactive Bladder (OAB) Bionic Drug Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 50. AbbVie Main Business
Table 51. AbbVie Latest Developments
Table 52. Astellas Pharma Details, CompanyType, Overactive Bladder (OAB) Bionic Drug Area Served and Its Competitors
Table 53. Astellas Pharma Overactive Bladder (OAB) Bionic Drug Product Offered
Table 54. Astellas Pharma Overactive Bladder (OAB) Bionic Drug Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 55. Astellas Pharma Main Business
Table 56. Astellas Pharma Latest Developments
Table 57. Pfizer Details, CompanyType, Overactive Bladder (OAB) Bionic Drug Area Served and Its Competitors
Table 58. Pfizer Overactive Bladder (OAB) Bionic Drug Product Offered
Table 59. Pfizer Overactive Bladder (OAB) Bionic Drug Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 60. Pfizer Main Business
Table 61. Pfizer Latest Developments
Table 62.Teva Details, CompanyType, Overactive Bladder (OAB) Bionic Drug Area Served and Its Competitors
Table 63.Teva Overactive Bladder (OAB) Bionic Drug Product Offered
Table 64.Teva Overactive Bladder (OAB) Bionic Drug Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 65.Teva Main Business
Table 66.Teva Latest Developments
Table 67. Johnson & Johnson Details, CompanyType, Overactive Bladder (OAB) Bionic Drug Area Served and Its Competitors
Table 68. Johnson & Johnson Overactive Bladder (OAB) Bionic Drug Product Offered
Table 69. Johnson & Johnson Overactive Bladder (OAB) Bionic Drug Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 70. Johnson & Johnson Main Business
Table 71. Johnson & Johnson Latest Developments
Table 72. Kyorin Pharmaceutical Details, CompanyType, Overactive Bladder (OAB) Bionic Drug Area Served and Its Competitors
Table 73. Kyorin Pharmaceutical Overactive Bladder (OAB) Bionic Drug Product Offered
Table 74. Kyorin Pharmaceutical Overactive Bladder (OAB) Bionic Drug Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 75. Kyorin Pharmaceutical Main Business
Table 76. Kyorin Pharmaceutical Latest Developments
Table 77.Tianjin Pacific Pharmaceutical Co., Ltd. Details, CompanyType, Overactive Bladder (OAB) Bionic Drug Area Served and Its Competitors
Table 78.Tianjin Pacific Pharmaceutical Co., Ltd. Overactive Bladder (OAB) Bionic Drug Product Offered
Table 79.Tianjin Pacific Pharmaceutical Co., Ltd. Overactive Bladder (OAB) Bionic Drug Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 80.Tianjin Pacific Pharmaceutical Co., Ltd. Main Business
Table 81.Tianjin Pacific Pharmaceutical Co., Ltd. Latest Developments
Table 82. Nanjing Meirui Pharma Co., Ltd. Details, CompanyType, Overactive Bladder (OAB) Bionic Drug Area Served and Its Competitors
Table 83. Nanjing Meirui Pharma Co., Ltd. Overactive Bladder (OAB) Bionic Drug Product Offered
Table 84. Nanjing Meirui Pharma Co., Ltd. Overactive Bladder (OAB) Bionic Drug Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 85. Nanjing Meirui Pharma Co., Ltd. Main Business
Table 86. Nanjing Meirui Pharma Co., Ltd. Latest Developments
Table 87. DIKANG Details, CompanyType, Overactive Bladder (OAB) Bionic Drug Area Served and Its Competitors
Table 88. DIKANG Overactive Bladder (OAB) Bionic Drug Product Offered
Table 89. DIKANG Overactive Bladder (OAB) Bionic Drug Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 90. DIKANG Main Business
Table 91. DIKANG Latest Developments
Table 92. Nanjing Zenkom Pharmaceutical Co., Ltd. Details, CompanyType, Overactive Bladder (OAB) Bionic Drug Area Served and Its Competitors
Table 93. Nanjing Zenkom Pharmaceutical Co., Ltd. Overactive Bladder (OAB) Bionic Drug Product Offered
Table 94. Nanjing Zenkom Pharmaceutical Co., Ltd. Overactive Bladder (OAB) Bionic Drug Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 95. Nanjing Zenkom Pharmaceutical Co., Ltd. Main Business
Table 96. Nanjing Zenkom Pharmaceutical Co., Ltd. Latest Developments



LIST OFFIGURES

Figure 1. Overactive Bladder (OAB) Bionic Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Overactive Bladder (OAB) Bionic Drug Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Overactive Bladder (OAB) Bionic Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Overactive Bladder (OAB) Bionic Drug Sales Market Share by Country/Region (2024)
Figure 8. Overactive Bladder (OAB) Bionic Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Overactive Bladder (OAB) Bionic Drug Market Size Market Share byType in 2024
Figure 10. Overactive Bladder (OAB) Bionic Drug in Idiopathic Overactive Bladder
Figure 11. Global Overactive Bladder (OAB) Bionic Drug Market: Idiopathic Overactive Bladder (2020-2025) & ($ millions)
Figure 12. Overactive Bladder (OAB) Bionic Drug in Neurogenic Overactive Bladder
Figure 13. Global Overactive Bladder (OAB) Bionic Drug Market: Neurogenic Overactive Bladder (2020-2025) & ($ millions)
Figure 14. Global Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Application in 2024
Figure 15. Global Overactive Bladder (OAB) Bionic Drug Revenue Market Share by Player in 2024
Figure 16. Global Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Region (2020-2025)
Figure 17. Americas Overactive Bladder (OAB) Bionic Drug Market Size 2020-2025 ($ millions)
Figure 18. APAC Overactive Bladder (OAB) Bionic Drug Market Size 2020-2025 ($ millions)
Figure 19. Europe Overactive Bladder (OAB) Bionic Drug Market Size 2020-2025 ($ millions)
Figure 20. Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size 2020-2025 ($ millions)
Figure 21. Americas Overactive Bladder (OAB) Bionic Drug Value Market Share by Country in 2024
Figure 22. United States Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 23. Canada Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 24. Mexico Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 25. Brazil Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 26. APAC Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Region in 2024
Figure 27. APAC Overactive Bladder (OAB) Bionic Drug Market Size Market Share byType (2020-2025)
Figure 28. APAC Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Application (2020-2025)
Figure 29. China Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 30. Japan Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 31. South Korea Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 32. Southeast Asia Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 33. India Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 34. Australia Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 35. Europe Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Country in 2024
Figure 36. Europe Overactive Bladder (OAB) Bionic Drug Market Size Market Share byType (2020-2025)
Figure 37. Europe Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Application (2020-2025)
Figure 38. Germany Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 39.France Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 40. UK Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 41. Italy Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 42. Russia Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 43. Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Region (2020-2025)
Figure 44. Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size Market Share byType (2020-2025)
Figure 45. Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size Market Share by Application (2020-2025)
Figure 46. Egypt Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 47. South Africa Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 48. Israel Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 49.Turkey Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 50. GCC Countries Overactive Bladder (OAB) Bionic Drug Market Size Growth 2020-2025 ($ millions)
Figure 51. Americas Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 52. APAC Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 53. Europe Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 54. Middle East & Africa Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 55. United States Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 56. Canada Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 57. Mexico Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 58. Brazil Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 59. China Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 60. Japan Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 61. Korea Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 62. Southeast Asia Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 63. India Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 64. Australia Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 65. Germany Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 66.France Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 67. UK Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 68. Italy Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 69. Russia Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 70. Egypt Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 71. South Africa Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 72. Israel Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 73.Turkey Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)
Figure 74. Global Overactive Bladder (OAB) Bionic Drug Market Size Market ShareForecast byType (2026-2031)
Figure 75. Global Overactive Bladder (OAB) Bionic Drug Market Size Market ShareForecast by Application (2026-2031)
Figure 76. GCC Countries Overactive Bladder (OAB) Bionic Drug Market Size 2026-2031 ($ millions)